Amgen Stock Rises on FDA Decision to Ease Imdelltra Monitoring Burden
Amgen Inc.'s stock gained 1.1 percent to close at USD 381.96 on Nasdaq on September 14, 2026, as investors reacted to a U.S. Food and Drug Administration decision that eased the monitoring burden for its bispecific T-cell engager therapy Imdelltra.
The FDA approved an update to the prescribing information for Imdelltra, reducing the recommended monitoring time for the first two doses from 22 to 24 hours to 6 to 8 hours in a healthcare setting. This change cuts monitoring time by roughly two-thirds and is accompanied by a follow-up assessment including vital signs on the day after each of these doses.
The decision comes as income-oriented investors focus on Amgen's dividend sustainability and valuation metrics. The company offers a dividend yield of 2.63 percent with a payout ratio of 44 percent and a three-year dividend growth rate of 7.1 percent, underscoring a steady income stream backed by earnings.
However, the broader narrative around Amgen stock has been shaped by negative news in the lipoprotein(a), or Lp(a), drug class. On September 4, 2026, Novartis reported that its pelacarsen trial did not demonstrate cardiovascular benefit, raising questions about the entire Lp(a)-lowering category that includes Amgen's investigational olpasiran.